Sanofi Wins FDA Nod for First Oral Gaucher Therapy, EU Approval for New Rabies Shot
SNY sits 18% above its 52-week low of $39.07 on light trading volume (0.1× avg).
Summary
Sanofi picked up two regulatory approvals Wednesday: the FDA cleared Infilbray (venglustat), an oral GCS inhibitor that crosses the blood-brain barrier, for neurological manifestations of Type 3 Gaucher disease in adults and pediatric patients. The approval rests on the LEAP2MONO Phase 3 trial, where Infilbray beat enzyme replacement therapy imiglucerase on a global test of neurological endpoints with statistical significance. Separately, the European Commission approved VaxRabeo, a Vero-cell rabies vaccine for pre- and post-exposure prophylaxis across all age groups, with better thermostability and a longer shelf life than Sanofi's current shots. Both are niche products — GD3 is a rare lysosomal storage disorder and rabies prophylaxis is a mature market — so near-term revenue impact is modest against a company of Sanofi's size. The bigger read is pipeline execution: this follows the October 30 Q3 beat and raised 2026 guidance, and adds two commercial assets to a portfolio already reshaped by the Regeneron immunology alliance and the Cheplapharm mature-medicine transfer. Shares were down 2.08% at $46.14 premarket, so the market is not treating the approvals as a needle-mover.
At the time of this announcement, SNY was trading at $46.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.5B. The 52-week trading range was $39.07 to $50.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.